Digest Network Come funziona
Network
/
Società
Im
Non verificato

ImmunityBio, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

42 comunicati stampa

Guarda tutti i comunicati
13/11/2025
Analisi di mercato
Industria
Scienza
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Sanità
Biotecnologia
Farmaceutica
Salute
Oncologia
New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0
05/11/2025
Mercato azionario
Oncologia
Salute
HIV, AIDS e malattie autoimmuni
Sanità
Farmaceutica
Biotecnologia
Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0
08/09/2025
Farmaceutica
Salute
Oncologia
Medicina - Varie
Web e Social Network
Eventi
Industria
ImmunityBio’s ANKTIVA® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0
26/08/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
Initial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With ImmunityBio’s ANKTIVA®, NK Cell Therapy Plus Optune Gio® Device
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0
19/08/2025
HIV, AIDS e malattie autoimmuni
Salute
Farmaceutica
Medicina - Varie
Industria
ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVID
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0
13/08/2025
Oncologia
Salute
Igiene alimentare
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Farmaceutica
Biotecnologia
Industria
ImmunityBio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free, First-In-Class CD19 CAR-NK Immunotherapy
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0
11/08/2025
Biotecnologia
Farmaceutica
Attrezzature medico-sanitarie
Oncologia
Salute
Sanità
Medicina - Varie
Industria
ImmunityBio Announces Houston’s Michael E. DeBakey VA Medical Center Is Among the First VA Hospitals to Administer ANKTIVA® to Bladder Cancer Patients
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0
05/08/2025
Attrezzature medico-sanitarie
HIV, AIDS e malattie autoimmuni
Igiene alimentare
Medicina - Varie
Management
Biotecnologia
Farmaceutica
Salute
Oncologia
Mercato azionario
Analisi di mercato
ImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-code
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0
25/07/2025
Biotecnologia
HIV, AIDS e malattie autoimmuni
Salute
Farmaceutica
Oncologia
Finanza
ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0
25/07/2025
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0